Triton, an investment firm, completed the acquisition of Clinigen, a global pharmaceutical and health-services company, for $1.8bn. StepStone is participating in the acquisition as a passive co-investor. "The Clinigen Board believes this offer represents an exceptional opportunity for Clinigen shareholders to realise value for their investment in cash at a very attractive valuation. We are therefore unanimously recommending it to our shareholders," Elmar Schnee, Clinigen Chairman. On January 11, 2022, Triton’s Clinigen bid wins support from proxy advisory firms. On January 17, 2022; Triton offers to acquire Clinigen for $1.8bn.